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Thousands of articles describing biomarkers predictive of treatment and prognostic of sur-
vival in cancer have been published, yet only a handful of biomarkers are currently used
routinely in the clinic. Biomarkers need to be analytically standardized, validated, and clini-
cally useful.This review will address the challenges and ways in which we can improve our
discovery and translation of prospective biomarkers from the lab into validated diagnostic
tests with a specific focus on patients diagnosed with glioblastoma and MGMT promoter
methylation status.There has been long-held enthusiasm to useMGMT promoter methyla-
tion as a predictive biomarker for patients treated with the alkylating agent, temozolomide;
however in the majority of centers around the world, this has not yet transpired.
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INTRODUCTION
The idea that we should be treating cancer patients on an individ-
ual basis has become a major objective in clinical oncology (Jain,
2002). In the past 10 years, more than 200,000 articles describing
biomarkers that predict treatment outcome have been published.
However, few biomarkers are currently used routinely in the clinic.
One very clear lesson learned is that anecdotal, underpowered bio-
marker studies have little clinical value and tend to significantly
slow down progress. Introduction into the clinic before appropri-
ate validation is costly and can result in the under treatment or over
treatment of patients (Dammann and Weber, 2012). The transla-
tion of prospective biomarkers from the lab into validated diag-
nostic tests is a major challenge. This review will focus upon the
discovery and development of biomarkers in glioblastoma (GBM).
DEFINITION OF A BIOMARKER
The critical hallmark of a biomarker is to be highly sensitive and
specific in providing information relevant for diagnosis, prognosis,
or therapy. There is no strict rule when it comes to what constitutes
a biomarker. A marker can consist of alterations of the genome,
epigenome, transcriptome, or proteome, aberrant microRNA as
well as imaging changes observed on a MRI or PET scan. The
most sought after biomarkers are the ones that can identify which
patients are at high risk of tumor relapse, and cytotoxicity in
response to specific chemotherapeutic agents. In addition, bio-
markers that can be easily ascertained by simple and inexpensive
methodologies such as immunohistochemistry (IHC) are also in
demand. The use of biomarkers to identify patients who do not
respond to treatment early could confer enormous benefits for
patients diagnosed with GBM, especially considering their usu-
ally short survival time. A few biomarkers have shown excellent
utility in survival prognostication but not necessarily at the level
of influencing an oncologist’s decision to administer a specific
drug or alter the treatment schedule. A summary of the key bio-
markers used for the diagnosis,prognosis and predicting treatment
response in GBM is provided in Table 1.
DIAGNOSTIC BIOMARKERS
BIOMARKERS TO DISTINGUISH PRIMARY GBM FROM SECONDARY
GBM
Primary GBM develops very fast de novo, without clinical or
histopathological evidence of a less malignant precursor lesion
(Scherer, 1940). Secondary GBM develops from low-grade dif-
fuse astrocytoma (LGA, WHO grade II) or anaplastic astrocytoma
(AA, WHO grade III). The pace of progression to a secondary
GBM varies considerably. The mean interval from LGA to sec-
ondary GBM is approximately 5 years; from AA to secondary GBM
is approximately 1.5–2 years.
From population-based clinical observations it has been esti-
mated that approximately 5% of all GBMs are secondary. However,
progression to secondary GBM may occur fast or asymptomatic
and thus escape clinical detection. They constitute a distinct
tumor entity with a significant difference in age distribution.
Primary GBMs affect the elderly, with a mean age at diagnosis
of approximately 60 years. Secondary GBM patients are approxi-
mately 15 years younger. They have a preferential location in the
frontal lobe, a lower Male/Female ratio and a significantly better
clinical outcome. Histopathologically, these two subtypes of GBM
cannot reliably be distinguished, however their genetic profile
differs significantly (Watanabe et al., 1996; Ohgaki et al., 2004).
The detection of mutations in the Krebs cycle enzyme isoci-
trate dehydrogenase (IDH) has become a reliable molecular test
for identifying secondary GBM. Using high-throughput next
generation sequencing, recurrent mutations in the active site of
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Table 1 | Biomarker summary.
Biomarker StandardizedTest? Diagnostic Use? Prognostic Use? Predictive Use? DruggableTarget?
MGMT promoter
methylation
No No Yes Yes No
MSP, pyrosequencing,
RT-PCR
Anaplastic glioma Elderly GBM
IDH1/2 mutation Yes Yes Yes No No
IHC (IDH1-R132H).
Sequencing
Can aid in the
differential diagnosis
of grade II/III glioma
from pilocytic
astrocytoma,
ependymomas and
reactive gliosis
Prognostically
favourable
Indicative of secondary
GBM
Mutant IDH1 is considered to
be a potentialtherapeutic
target; however no
treatments are available as
yet
Can detect the
infiltration of tumor
cells in normal tissue
TP53mutation No Yes No No No
IHC is commonly used
however this is not
representative of a
mutation
Genetic hallmark in
60-70% of low-grade
diffuseastrocytomas,
anaplastic
astrocytomas and
secondary GBMs
Some studies have
found a shorter time
interval to progression
in patients with TP53
mutant low-grade
astrocytoma
EGFR
amplification
Yes Limited No No Yes
IHC does not
differentiate between
EGFR amplification and
overexpression
EGFR amplification
indicates primary
GBM
Cetuximab
Erlotinib
Gefitinib
EGFRvIII:
rhindopepimut
VEGF No No No No Yes
IHC, but not used
clinically
bevacizumab
IDH1 have been identified in approximately 12% of all GBM
and were typically observed in younger patients with secondary
GBM (Parsons et al., 2008). Since the IHC test for IDH muta-
tion detection was introduced to the clinic, secondary GBMs have
been shown to constitute approximately 10% of all GBMs (pre-
viously estimated at 5% on the basis of a known precursor lesion
and age; Nobusawa et al., 2009). Point mutations at the argi-
nine 132 (IDH1) and at arginine 140 or arginine 172 (IDH2)
in the active site of IDH enzyme alter catalytic activity of the
enzyme and results in increased production of 2-hydroxyglutarate
(2-HG) which is potentially associated with increased cancer
risk and glioma progression (Dang et al., 2009). A recent study
showed that 2-HG also had a potential to competitively inhibit α-
ketoglutarate-dependent enzymes including histone demethylases
and 5-methylcytosine hydroxylases which in turn leads to genome-
wide histone modifications and DNA methylation changes (Xu
et al., 2011).
Additionally, mutations in the tumor suppressor TP53 are
observed in 70% of secondary GBM (Ohgaki and Kleihues, 2007).
TP53 negatively regulates the proliferation of cells and plays an
important role in the transcriptional activation or repression of
several genes, in particular p21, an inhibitor of cyclin-dependent
kinases [CDKs]). Through this pathway, TP53 mediates cell cycle
control at G1/S and G2/M checkpoints (Agarwal et al., 1995).
Many laboratories use IHC to detect TP53 expression, but in
CNS tumors, immunoreactivity is not representative of the gene
mutation status.
PROGNOSTIC BIOMARKERS
CLASSICAL PHENOTYPICAL TRAITS
By definition, a prognostic marker has the capacity to estimate sur-
vival outcome, independent of whether or not the patient receives
adjuvant radiation therapy (RT) and/or chemotherapy. Classical
phenotypical traits that are prognostic for survival include age,
performance status, tumor location, and histological grade. Older
age has been consistently associated with poor prognosis. In a
historical population-based study, there was a linear decrease of
overall survival with increasing age. Patients aged 70–79 years
had a median survival of 2.9 months, those above 80 years only
1.9 months (Ohgaki et al., 2004). Similarly, a high preoperative
performance status has a favorable prognostic impact, irrespective
of subsequent adjuvant therapy (Lacroix et al., 2001; Whittle et al.,
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2002; Buckner, 2003). Size and location are also highly prognostic,
with the worst outcome for GBMs being tumors that have spread
extensively, e.g., across the corpus callosum to the contralateral
hemisphere (Buckner, 2003).
USING GENOMIC CHANGES IN GBM AS A DIAGNOSTIC TOOL TO
SELECT PATIENTS FOR TARGETED THERAPY
GBM is highly heterogeneous. The 2007 World Health Organi-
zation (WHO) classification of tumors lists giant cell GBM and
gliosarcoma as histological variants of GBM. These rare subtypes
reflect the marked genomic instability of the tumors. However the
variable survival times of patients suggests that there are multiple
subtypes of GBM. The genetic profiling of large tumor cohorts
with comprehensive clinical and survival data has promoted the
discovery of novel molecular biomarkers associated with survival,
in addition to traditional clinical and morphological features (Nutt
et al., 2003; Rich et al., 2005; Colman et al., 2010; Verhaak et al.,
2010). In GBM, comprehensive gene sequencing performed by
The Cancer Genome Atlas (TCGA) has identified an average of 47
mutations per tumor, although far fewer were candidates to be dri-
ver mutations (Parsons et al., 2008). Driver mutations were most
frequent in the TP53, RB1, and PI3K/PTEN pathways. Mutations
in these pathways were generally mutually exclusive, suggesting
that they are key to tumorigenesis, and functionally equivalent
(Parsons et al., 2008).
At least two distinct cluster profiles have been identified:
proneural and mesenchymal-angiogenic signatures, which dif-
fer in survival and response to treatment (Colman et al., 2010;
Verhaak et al., 2010). Verhaak et al. (2010) performed consen-
sus clustering on the results of TCGA gene expression arrays
from 200 samples of GBM, proposing classification into not two,
but four subtypes: proneural, neural, classical, and mesenchy-
mal. Younger age and longer survival were common features of
patients with proneural subtypes. Patients benefiting from con-
current chemotherapy were associated with the classical GBM
subtype. The mesenchymal GBM subgroup was connected with
poor survivorship. Similar frequently mutated genes were identi-
fied to previous work, including TP53, PTEN, NF1, EGFR, IDH1,
PIK3R1, RB1, ERBB2, EGFRvIII, PIK3CA, and PDGFRA. They
identified clinical correlations, for example with younger age and
proneural subtype, as well as survival differences by treatment,
such as benefits from combined chemoradiotherapy in the classical
subtype which were not seen in the proneural subtype. Secondary
GBMs with IDH1/2 mutations have almost always a proneural
signature.
Unfortunately no single classification is yet regarded as defin-
itive, and our use of technology and understanding of what is
clinically translatable continues to evolve (Vitucci et al., 2011). A
comprehensive study of microarray data from four different inde-
pendent data sets by Colman et al. (2010) identified a 38-gene
signature associated with survival (31 genes associated with poor
survival outcome). A smaller 9-gene signature based upon the
38 genes was tested on FFPE tissue from patients enrolled in the
RTOG 0825 Phase III trial of newly diagnosed GBM.
There is a lack of confidence from biologists and diagnostic
laboratories to use the 9-gene signature and/or to group GBM
according to subtypes because the literature keeps changing. In a
more recent study by Shen et al. (2012), three distinct GBM sub-
types were identified using integrative subtype analysis of TCGA
GBM dataset. There were overlaps between the Verhaak and Cole-
man studies but there were also striking differences. However,
there is consensus in the neuro-oncology community to sub-
type GBM, even if it is into the broader groups of proneural and
mesenchymal or suptype 1 and 3. Clinical trial efficacy with pre-
selected patient populations will improve. It is anticipated that
the IDH1/2 mutational status will prove to be most reliable and
significant.
GENOTYPE-DIRECTED THERAPY (DRUGGABLE
BIOMARKERS)
EPIDERMAL GROWTH FACTOR RECEPTOR
Tumors belonging to the subtype 2 described by Shen and col-
leagues or the “classical” subtype coined by Verhaak and colleagues
are associated with Epidermal growth factor receptor (EGFR) copy
number amplification. This is the most common EGFR alteration
found in 30–50% of GBM patients, leading to increased EGFR
expression, activity of the EGF pathway, cell growth, and prolif-
eration (Shinojima et al., 2003). EGFR amplified tumors can also
harbor mutations, with the most common being an in-frame dele-
tion of exons 2–7 (known as EGFR vIII ; Pelloski et al., 2007). This
deletion is present in 50–60% of GBM patients with EGFR ampli-
fication (Del Vecchio et al., 2012). EGFR overexpression detected
by IHC is not representative of EGFR amplification, yet this test is
commonly used.
Because of the frequency of EGFR aberrations, it is not sur-
prising that there have been concerted efforts to therapeutically
target EGFR. Inhibitors have been approved for use in non-small
cell lung cancer (NSCL) and have gone to clinical trial in GBM;
however the results have been very disappointing. Many patients
with GBM either do not respond to these inhibitors from the
outset and those patients that do respond, end up developing
resistance. Cetuximab (Erbitux) has been shown to act syner-
gistically in combination with cytostatic drugs and radiotherapy.
More recently it has been shown that GBMs carrying a novel exon
27 deletion mutation (EGFR-CTD) respond better to cetuximab
(Cho et al., 2011). Small molecule tyrosine kinase inhibitors (TKIs)
including erlotinib (Tarceva®) and gefitinib (Iressa®) have also
been investigated in GBM trials with disappointing outcomes.
Recently these poor results have been attributed to the differ-
ent conformational requirements of mutant EGFR in NSCL and
GBM (Vivanco et al., 2012). EGFR inhibitors that target the active
kinase conformation such as erlotinib are ineffective as a result
of mutations or deletions in the extracellular domain resulting
in EGFR addiction (Vivanco et al., 2012). NSCL susceptible to
EGFR treatment tend to harbor mutations in the EGFR kinase
domain.
The PTEN tumor suppressor gene also plays a key role in resis-
tance to EGFR inhibitors. Loss or mutation of this gene occurs in
∼40% of GBM. Functional PTEN (retention of activity) has been
linked to favorable response to erlotinib (Mellinghoff et al., 2005)
however this could not be confirmed clinically (van den Bent et al.,
2009). Additionally, phosphorylation of the conserved residue of
Y240 in GBM has been shown to be associated with resistance to
EGFR therapy (Fenton et al., 2012).
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VASCULAR ENDOTHELIAL GROWTH FACTOR
Vascular Endothelial Growth Factor (VEGF) is highly expressed
in GBM and is a critical component of the pathophysiology
(Folkman, 1995; Jain et al., 2007) and numerous experimental
studies have supported a major role for VEGF in tumor angiogen-
esis (Dowlati and Fu, 2008). Blocking VEGF leads to impeded
vessel growth and endothelial cell proliferation, vasoconstric-
tion and vessel “normalization” which results in redistribution of
blood flow in tumor tissue and improves delivery of anti-cancer
agents to individual cells (McVicker and Tabatabai, 2006; Weiner
et al., 2006). Bevacizumab targets VEGF-2, while the drugs cedi-
ranib (Wachsberger et al., 2011) and sunitinib (D’Amico et al.,
2012) target also VEGFR-1, -2, and -3. The efficacy of cedi-
ranib was trialed in a Phase III study of recurrent GBM patients
as a monotherapy and in combination with lomustine versus
lomustine alone (REGAL study). Although there was evidence of
activity, cediranib treatment did not improve survival (Ahluwalia,
2011).
The use of bevacizumab as a second line treatment for GBM was
fast-tracked in the USA 3 years ago (Cohen et al., 2009; Clough-
esy, 2010). FDA approval was based on positive results from two
prospective phase II trials on patients with relapsed tumors (Vre-
denburgh et al., 2007; Friedman et al., 2009). Although close to
half of patients treated with bevacizumab show a dramatic radi-
ological response rate and an increased median progression free
survival (PFS) compared to historic controls, no impact on overall
survival has been reported (Friedman et al., 2009; Chamberlain,
2011).
SUMMARY OF THE CURRENT STATE OF GENOTYPE-DIRECTED THERAPY
There is no doubt that genotype-directed medicine holds great
promise for the treatment of tumors. However, we recognize that
a multi-facetted, combination therapy approach will be necessary.
In addition, what works in one cancer such as the EGFR inhibitors
in NSCLC may not be effective in another solid cancer harbor-
ing the same mutation as a result of conformational changes.
Additionally, there strong cross talk between the signaling path-
ways significantly adds to the complexities of genotype-targeted
treatment of a tumor. Subtyping of GBM prior to clinical trial
is essential. Clinical and research laboratories need to agree on a
minimal molecular testing platform, whether it be the gene signa-
tures or the testing of individual molecular markers and agreement
on the methodologies must come into play.
BIOMARKERS WITH TREATMENT PREDICTIVE VALUE
Much more difficult to identify are biomarkers with predictive
power in the context of a specific therapy. Predictive biomarkers
are markers that can be used to identify groups of patients who
are most likely to respond to a given treatment. The key difference
between a prognostic and a predictive biomarker is that a predic-
tive biomarker should instigate a change in the treatment provided
to the patient.
O6-METHYLGUANINE-DNA METHYLTRANSFERASE: IS METHYLATION
OF MGMT PREDICTIVE OF RESPONSE TO TEMOZOLOMIDE?
Detection of methylation within the promoter region of O6-
methylguanine-DNA methyltransferase (MGMT ) gene has clearly
provided the most meaningful clinical correlation and is generally
accepted as a predictive and prognostic biomarker in temozolo-
mide treated GBM, even in elderly patients (Stupp et al., 2005a,
2009; Reifenberger et al., 2012; Wick et al., 2012). TheMGMT gene
is located on chromosome 10q26.1 and encodes a DNA repair pro-
tein that restores mutagenic O6-alkylguanine to normal guanine
within genomic DNA. Alkylating drugs such as temozolomide
are used in chemotherapy for the targeted cell death of rapidly
replicating neoplastic cells and MGMT expression is a key factor
in conferring resistance to these agents. Loss of MGMT protein
expression is frequently associated with transcriptional silencing
of the MGMT gene by methylation of its CpG island promoter in
various neoplasia, (Esteller et al., 1999) as exemplified by 35–55%
of gliomas (Silber et al., 1999; Esteller et al., 2001; Nakamura et al.,
2001; Kamiryo et al., 2004; Brell et al., 2005; Hegi et al., 2005).
There has been considerable and long-held enthusiasm to use
MGMT as a predictive biomarker for glioma patients, with the
longer term hope for its use as a marker to assign therapy to
individual patients. Three criteria for predictive biomarkers were
recently developed by the Evaluation of Genomic Applications
in Practice and Prevention (EGAPP) Working Group convened by
the Centers for Disease Control: (1) Analytical validity; (2) Clinical
Validity; and (3) Clinical Utility. We herein apply these paradigms
to MGMT as a predictive biomarker.
Analytical validity
Pre-analytical and analytical factors that contribute to accuracy,
reliability and reproducibility of the specific assay test for MGMT
promoter methylation testing has become a controversial issue.
There is still no consensus on the optimal method to be applied.
Assessment of MGMT promoter methylation is difficult due to
the complex nature of the techniques involved. To detect methyla-
tion, bisulfite treatment of the DNA is required, a process that
may result in degradation of DNA and subsequent low suc-
cess rates in PCR. This is further compounded by the fact that
the most commonly available tissue for assessment is FFPE, and
the DNA subsequently extracted is typically fragmented, again
making PCR more difficult. Promoter methylation analysis by
qualitative methyl-specific polymerase chain reaction (MSP) or
semi-quantitative methyl-specific polymerase chain reaction (SQ-
MSP), especially from FPPE tissue is technically demanding. MSP
is the more limited because the methylation status of only a few
CpG sites (i.e., those interfering with the PCR primer binding) can
be interrogated at once. The technique also has the drawback of
providing only a qualitative indication of the methylation status of
the sites. Karayan-Tapon et al. (2010) evaluated MGMT promoter
methylation using MSP, SQ-MSP, and pyrosequencing. The best
predictive value for overall survival was obtained by pyrosequenc-
ing which is a technique that generates a quantitative measure
of methylation and automatically calculates and reports percent
methylation for each CpG site in the studied sequence, thus allow-
ing detection of partially methylated CpG sites. The problem with
pyrosequencing, however, is the different % cut-offs for methy-
lation and clinical relevance of the cut-off chosen. Two regions
tightly associated with patient survival were recently identified
by Bady et al. (2012) using an Infinium methylation BeadChip.
The latter of the two regions is within the 59 bp enhancer region,
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between the exon 1 and intron boundary of the MGMT gene. The
majority of PCR assays, including the MSP and pyrosequencing,
target this region.
Clinical validity
O6-methylguanine-DNA methyltransferase promoter methyla-
tion status is clinically well founded. In 2005, in a companion
study conducted on tumor specimens from patients enrolled in
the EORTC_26981/NCIC_CE.3 (Stupp et al., 2005b), Hegi et al.
(2005) demonstrated a pronounced favorable response in patients
whose tumors had lost MGMT activity via promoter methylation.
The median survival for patients with methylated MGMT was
21.7 months compared to 12.7 months for patients with unmethy-
lated MGMT. MGMT status can reliably distinguish two or more
subgroups within a population that have different biological and
clinical outcomes and has been used to stratify patient populations
in a number of Phase II trials (Grossman et al., 2009; Fabi et al.,
2010; Peereboom et al., 2010; Weiler et al., 2010; Lai et al., 2011).
The strong prognostic role for MGMT promoter methylation in
GBM treated with concurrent RT and TMZ was prospectively con-
firmed by the Radiation Therapy Oncology Group (RTOG) study
0525 (Ahluwalia, 2011).
The testing of patients for MGMT promoter methylation has
been incorporated in numerous trials. A better response to cilen-
gitide treatment in a phase I/IIa trial was observed in MGMT
methylated patients (Stupp et al., 2010). In response, recruit-
ment to the Phase III trial; Cilengitide, Temozolomide, and RT
in Treating Patients With Newly Diagnosed GBM and Methylated
Gene Promoter Status [CENTRIC]; NCT00689221 was restricted
to patients with MGMT promoter methylation. The outcome of
this trial is not yet known. The RTOG 0825 trial (mentioned
earlier), examining the effect of bevacizumab administered with
radiotherapy compared to conventional concurrent chemora-
diotherapy (TMZ) in primary GBM also incorporated MGMT
promoter methylation testing for all patients (Colman et al.,
2010).
Two studies exploring the different treatment regimes in the
elderly (patients aged over 60 years and diagnosed with a GBM):
the German Neuro-oncology Group trial, NOA-08 (Wick et al.,
2012) and the Nordic study (Malmstrom et al., 2012), also showed
that MGMT promoter methylation was both prognostic and pre-
dictive for response to alkylating therapy. In both studies, survival
was significantly improved in the MGMT methylated patients
when treated with temozolomide, thus establishing MGMT as
a predictive biomarker in this patient population. In contrast,
MGMT promoter methylation appears to have no predictive
capacity in anaplastic glioma. The NOA-04 trial showed a striking
difference in PFS between patients with versus without MGMT
promoter methylation who were treated with radiotherapy alone
(Wick et al., 2012).
Clinical Utility
Clinical validity does not imply that a tumor biomarker assay
should be used to care for patients. Prospective testing of elderly
GBM patients for MGMT to determine if they should receive
temozolomide is a significant advancement in clinical treat-
ment. If MGMT methylated, up front temozolomide will be
offered to this patient group. Importantly, these patients will be
spared the radiotherapy which may lead to significant deficits
including tiredness and memory loss. MGMT promoter methy-
lation can also help to distinguish true tumor progression from
pseudoprogression. Park et al. (2011) combined MS-MLPA and
MSP methodologies for detecting MGMT methylation of which
resulted in a diagnostic accuracy of 93% for the identification
of pseudoprogression as opposed to radiological progression in
GBM patients. It is critical to distinguish pseudoprogression
because misinterpretation can lead to early treatment cessation
or surgery.
The usefulness of testing for MGMT promoter methylation
in all GBM patients in a routine clinical setting will come to
fruition when an alternative treatment strategy is available. Until
then, it is difficult and highly contentious for clinicians to base
their decisions on whether or not they should withhold temozolo-
mide treatment in patients with unmethylated MGMT and a good
performance status.
With this recognition that an unmethylated MGMT promoter
is associated with a poorer response to temozolomide, strategies
have evolved to circumvent the resistance that MGMT confers.
Numerous studies, including the multicenter RTOG 0525 have
examined altered TMZ dosing regimes, but no significant survival
benefits have been conferred (Brock et al., 1998; Wick et al., 2007,
2009; Perry et al., 2008; Ahluwalia, 2011). The MGMT unmethy-
lated population of patients needs to be put on center stage for
new treatment strategies.
THE FUTURE OF BIOMARKER DISCOVERY AND
IMPLEMENTATION INTO THE CLINIC
We need to review where we are going wrong with biomarker
discovery and development and identify the steps required to
improve their clinical value and utility. First and foremost,
we need to be asking the right questions. Is this biomarker
involved in driving the cancer growth? Is this biomarker drug-
gable? And of upmost importance, is it clinically relevant?
Will this biomarker lead to a clinician altering their clini-
cal decision? The collection of quality preserved tumor tis-
sue that has undergone independent histological review will
improve biomarker discovery. In the cases where biomarkers
have been identified, standardized testing needs to be imple-
mented.
IMPORTANCE OF HIGH QUALITY TUMOR BANKING
The majority of biomarkers stem from studies on tumor tis-
sue. Less than perfect tissue will lead to false-positives. Sub-
standard tissue and data collection provided a significant obstacle
to the TCGA effort. Standard operating procedures (SOPs) are
not consistent between sites, and sometimes differ within single
institutions. Methodologies for preserving tissue vary and times
between tumor removal and time of processing fluctuate. Signif-
icant changes can occur between the time interval between tissue
removal and processing. Despite this knowledge, in many cen-
ters, biorepositories remain underfunded. The collection of tissue
needs to be taken seriously and investments are essential to pro-
mote basic, translational, and clinical research as well as social gain
in terms of improved cancer care and economic development.
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The same standards should apply to FFPE. However, unlike for
frozen tissue, the time intervals taken for preservation are usu-
ally not recorded. Enrollment onto clinical trials is now often
dependent upon receipt of FFPE tissue for central pathology and
additional molecular tests such as Ion Torrent PMG sequencing
which is a tailored platform to cater for FFPE tissue. Experience at
one site in Australia revealed that FFPE specimens from patients
operated between Monday-Thursday typically passed quality con-
trol and DNA extracted from these tissues tended to be suitable
for sequencing. However, there were a sizeable number of FFPE
samples that did not make the grade. These samples were usually
from patients who were operated on a Thursday evening or a Fri-
day. An investigation of the problem revealed that the specimens
were kept in formalin solution for up to 72 h because samples were
not processed over the weekend.
HISTOLOGICAL REVIEW
Histological classification of gliomas shows a significant inter-
observer variability, particular in the distinction of astrocytomas
vs. oligodendrogliomas and oligoastrocytomas (Kim et al., 2010).
Similarly, the diagnosis of anaplastic astrocytoma can be very
challenging (van den Bent, 2010). GBMs can easily be classified
as anaplastic astrocytoma if the histological hallmarks necro-
sis and/or microvascular proliferation are not detected due to
a sampling error. There is a need that all glioma diagnoses be
complemented by a minimum set of genetic characteristic, includ-
ing IDH1 and TP53 mutation, 1p/19q co-deletion, and EGFR
amplification.
STANDARDIZATION OF METHODOLOGY FOR BIOMARKER TESTING
There is also an apparent lack of standardization in the methods
used for biomarker measurement. Assays for biomarkers need to
be reliable. The assay needs to give identical results if repeated in
the same or in another laboratory. The result needs to be the same,
even when different methodologies are used. And finally, we need
to ask whether the test provides added value to clinical practice.
TCGA analyses have identified a high diversity of genes mutated
within GBM. As prices drop with Next Generation sequencing,
capabilities to better define genetic aberrations associated with
response to a specific treatment will improve. Copy number aber-
rations (amplifications and deletions) and structural aberrations
(intra-chromosomal rearrangements-inversions, inverted/tandem
duplications) are not detected using traditional Sanger sequenc-
ing. Our ability to assess these aberrations must improve at the
rate that targeted therapies emerge.
CONCLUSION
To advance personalized medicine, a co-operative effort between
cancer researchers and clinicians is needed. There is also insuf-
ficient collaboration within various scientific teams working on
targeted therapies such as the TKIs and anti-angiogenics. Specific
consideration needs to be paid to increasing sample sizes, sequenc-
ing entire genes, implementing robust methodologies and taking a
holistic approach to understanding pathways. Cancer is multifac-
eted and it is our task to unravel these complexities. With highly
integrated teams of multidisciplinary investigators, a better overall
survival of GBM patients is achievable.
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